MT-ND4L is a core subunit of complex I (NADH:ubiquinone oxidoreductase), which catalyzes the transfer of electrons from NADH to ubiquinone in the mitochondrial inner membrane . This process generates a proton gradient essential for ATP synthesis during oxidative phosphorylation. Mutations in homologous human MT-ND4L genes are linked to Leber hereditary optic neuropathy, a mitochondrial disorder causing vision loss .
The recombinant protein is produced in E. coli using optimized conditions to ensure proper folding and solubility. Key steps include:
Cloning: Insertion of the MT-ND4L gene into a plasmid vector.
Fermentation: High-density E. coli cultures for protein expression.
Purification: Affinity chromatography (via His-tag) followed by size-exclusion chromatography .
Complex I Assembly: ND4L is essential for the assembly of the 950-kDa complex I holocomplex. Its absence disrupts electron transport and ATP production .
ELISA Development: Recombinant MT-ND4L serves as an antigen in ELISA kits for detecting anti-complex I antibodies or studying mitochondrial dysfunction .
While the recombinant protein itself is not therapeutic, it aids in understanding mitochondrial complex I deficiencies. For example: